Clinical strategy for generic of biosimilar [Regulatives / Guidelines]

posted by qualityassurance – 2025-01-09 09:41 (179 d 11:59 ago) – Posting: # 24332
Views: 1,657

Dear Experts,

We are developing generic oral tablets formulation for one of the biosimilar product. However, API that we will use in our product will be synthetic while in RLD it is r-DNA based API.

For EMA submission, which guideline should we follow to derive clinical pathway considering above? I have come across various guidelines such as 1) Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins, 2) Guideline on similar biological medicinal products, 3) Biosimilars in the EU: Information guide for healthcare professionals. But not sure if i am referring to the correct guidelines.

Is there a need to conduct toxicology and immunogenicity study or only BE study will be suffice?

Looking forward for valuable feedback.

Regards,
QA

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,686 registered users;
78 visitors (0 registered, 78 guests [including 12 identified bots]).
Forum time: 22:41 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5